Edition:
United Kingdom

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

2.64USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$2.64
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
44,604
52-wk High
$7.68
52-wk Low
$2.54

Chart for

About

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.... (more)
No analyst recommendations are available for .

Overall

Beta: 1.10
Market Cap(Mil.): $7.14
Shares Outstanding(Mil.): 2.59
Dividend: --
Yield (%): --

Financials

  RXII.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -5.67 -- --
ROI: -196.28 -0.73 12.97
ROE: -271.79 -2.77 14.84

BRIEF-Intracoastal Capital LLC Reports 9.2 Pct Passive Stake In RXI Pharmaceuticals Corp, As Of April 9

* INTRACOASTAL CAPITAL LLC REPORTS 9.2 PERCENT PASSIVE STAKE IN RXI PHARMACEUTICALS CORP, AS OF APRIL 9, 2018 - SEC FILING Source text: [https://bit.ly/2vwj7uq] Further company coverage:

18 Apr 2018

BRIEF-Lincoln Park Capital Reports 9.99 Pct Passive Stake In Rxi Pharmaceuticals

* LINCOLN PARK CAPITAL FUND, LLC REPORTS 9.99 PCT PASSIVE STAKE IN RXI PHARMACEUTICALS CORP AS OF APRIL 9, 2018 SEC FILING Source: (https://bit.ly/2HzQ63m) Further company coverage:

13 Apr 2018

BRIEF-Rxi Pharmaceuticals Announces Closing Of $4.9 Million Registered Direct Offering

* RXI PHARMACEUTICALS ANNOUNCES CLOSING OF $4.9 MILLION REGISTERED DIRECT OFFERING Source text for Eikon: Further company coverage:

11 Apr 2018

BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market

* RXI PHARMACEUTICALS ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

09 Apr 2018

BRIEF-Rxi Pharmaceuticals Files For Mixed Shelf Of Upto $100 Million

* RXI PHARMACEUTICALS CORP FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING Source text: (https://bit.ly/2If6FB2) Further company coverage:

29 Mar 2018

BRIEF-RXI Says Determined Interim Financial Statements For Qtrs Ended March 31, June 30, Sept 30, 2017 Should No Longer Be Relied Upon‍​

* RXI - ON MARCH 20, DETERMINED INTERIM FINANCIAL STATEMENTS FOR QTRS ENDED MARCH 31, JUNE 30, AND SEPT 30, 2017 SHOULD NO LONGER BE RELIED UPON‍​

26 Mar 2018

BRIEF-RXi Pharmaceuticals Qtrly Loss Per Share $0.84

* RXI PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

26 Mar 2018

BRIEF-RXi Pharmaceuticals Announces Business Strategy To Focus On Immuno-Oncology Programs To Accelerate Growth

* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH

16 Jan 2018

BRIEF-RXi Pharmaceuticals Announces Reverse Stock Split

* RXI PHARMACEUTICALS CORP - ANNOUNCED A REVERSE STOCK SPLIT OF ITS SHARES OF COMMON STOCK AT A RATIO OF 1-FOR-10

05 Jan 2018

BRIEF-RXi Pharma Announces Meets Secondary Objective With RXI-109 For Dermal Scarring

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH RXI-109 FOR DERMAL SCARRING

18 Dec 2017

Earnings vs. Estimates